DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing a digital twin of human cells to accelerate drug discovery.
The DeepLife team develops a SaaS platform combining state-of-the-art machine learning algorithms on single cell multi-omics data, public and private cell atlases, and a proprietary deep learning-based digital twin. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior.
We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.